新植二烯
| 中文名称 | 新植二烯 |
|---|---|
| 中文同义词 | 新植二烯;NEOPHYTADIENE (80%);7,11,15-三甲基-3-亚甲基十六碳-1-烯;维生素 K1杂质64 |
| 英文名称 | 7,11,15-trimethyl-3-methylidene-hexadec-1-ene |
| 英文同义词 | 7,11,15-trimethyl-3-methylidene-hexadec-1-ene;2-(4,8,12-Trimethyltridecyl)-1,3-butadiene;2-(4,8,12-Trimethyltridecyl)buta-1,3-diene;3-Methylene-7,11,15-trimethylhexadec-1-ene;7,11,15-Trimethyl-3-methylene-1-hexadecene;1,3-Butadiene, 2-(4,8,12-trimethyltridecyl)-;1-Hexadecene, 7,11,15-trimethyl-3-methylene-;Hsdb 4321 |
| CAS号 | 504-96-1 |
| 分子式 | C20H38 |
| 分子量 | 278.52 |
| EINECS号 | |
| 相关类别 | 中药对照品;标准品;All Aliphatics;Aliphatics;Inhibitors |
| Mol文件 | 504-96-1.mol |
| 结构式 |  |
新植二烯 性质
| 沸点 | 144-146 °C(Press: 3.5 Torr) |
|---|---|
| 密度 | 0.8168 g/cm3 |
| 储存条件 | -20°C Freezer |
| 溶解度 | 苯（少量溶解）、氯仿（可溶）、乙酸乙酯（少量溶解） |
| 形态 | 油状 |
| 颜色 | 无色 |
| 稳定性 | 对光敏感、对温度敏感 |
| InChI | InChI=1S/C20H38/c1-7-18(4)12-9-14-20(6)16-10-15-19(5)13-8-11-17(2)3/h7,17,19-20H,1,4,8-16H2,2-3,5-6H3 |
| InChIKey | NIDGCIPAMWNKOA-UHFFFAOYSA-N |
| SMILES | C=CC(=C)CCCC(C)CCCC(C)CCCC(C)C |
| LogP | 9.522 (est) |
| EPA化学物质信息 | 1-Hexadecene, 7,11,15-trimethyl-3-methylene- (504-96-1) |
Neophytadiene has cytotoxic on RAW 264.7 cells with an IC
50
of 50 μM.
Neophytadiene (50-100 μM; 30 min) successfully inhibits the NO production level and downregulated inducible nitric oxide synthase (iNOS) production in LPS (1 μg/mL)-induced RAW264.7 cells.
Neophytadiene (25-100 μM; 22 hours) significantly inhibits the NO production and inflammatory cytokines TNF-α, IL-6 and IL-10 and IL-10 in LPS (1 μg/mL)-induced RAW264.7 cells.
Neophytadiene (50 mg/kg; p.o.) shows dose-dependent reduction in the alanine aminotransferase (ALT) level.
Neophytadiene (25-50 mg/kg; p.o.) significantly reduces LPS (10 mg/kg)-increased IL6 and 1L10 levels and in heart tissue.
Neophytadiene (25-50 mg/kg; p.o.) significantly reduces LPS (10 mg/kg)-increased PGE2mRNA expression in heart tissue.
Neophytadiene significantly inhibits LPS (10 mg/kg)-induced NO production and inflammatory cytokines TNF-α, IL-6 and IL-10 and IL-10 in vivo.
| Animal Model: | Adult male Sprague Dawley rats (6-8 weeks) |
| Dosage: | 12 mg/kg, 25 mg/kg, 50 mg/kg |
| Administration: | Oral administration, daily, for 7 days |
| Result: | Decreased haemoglobin (HGB) level, ALT level, and heart tissue TNF-α, IL1β, NF-κB, iNOS, PI3k/AktandMAPK in LPS (10 mg/kg)-treat rats. |